Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, to kick things off, Regeneron has announced a one billion dollar upfront deal with Alnylam to use its RNA platform for their R&D projects this week. … Read more
Welcome back everybody to another edition of “BioPharma Bitez.” The top news in the industry, as well as one story outside of it. Now with even more branding. So, to kick it off this week, the NCI head Ned Sharpless has been named the acting FDA Commissioner this week, which… Read more
Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. So, to kick things off this week, AbbVie has boosted its, “multiple myeloma” program with a new million dollar in “teneobio” who specializes in heavy chain antibodies.… Read more
Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off, Alkermes says, and LCFD has rejected the NDA for their top-of-the-line depression drug this past week. GSK is now co-developing a fusion protein… Read more
Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off in the past week, UK Biotechs had a record year of vesting with over 1.1 billion pounds which is about 1.44 billion dollars vested… Read more
Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And stick around to for a new segment that I have added on. So, to kick it off this week, Celgene continues their deal-making campaign with Kyn… Read more
Happy Friday everybody, welcome to this week’s edition of “BioPharma Bitez.” Top news in the industry as well as one story outside of it. Now, with a new, shinier, backdrop! So, to kick it off this week, Verona suffered a “phase two failure” for a COPD bronchodilator product. It would… Read more
Happy Friday everybody, welcome to this week’s edition of “BioPharma Bitez.” The tops news in the industry as well as one story outside of it. So, obviously, J.P. Morgan was this week, so, some of the stories that came out of that: Eli Lilly has bought Loxo for 8 billion… Read more
Happy Friday everybody! Welcome to this week’s edition of “BioPharma Bitez”, the top news of the industry as well as one outside of it. So, to kick it off this week, the obvious story is GSK buying Tesaro for 5 billion dollars. This will actually expand GSK’s commercial oncology portfolio. We… Read more
I wanted to continue the discussion with effective marketing strategies. All of these tips should be used in tandem. So, we’ve got “MPC marketing” finding those impact players, critically important. Building your brand through social media, doing a post, just getting active in those areas. Do more today than… Read more